 |
50 Diseases |  |
11 Trials |
|
11 Trials |  |
833 News |  |
| «123456789101112» |
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P3 trial: Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (clinicaltrials.gov) - Dec 19, 2017
P3b, N=347, Completed, Sponsor: Astellas Pharma Inc
- ||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (clinicaltrials.gov) - Dec 19, 2017
P2, N=124, Completed, Sponsor: Astellas Pharma Inc
- ||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (clinicaltrials.gov) - Dec 19, 2017
P3b, N=347, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Phase classification: Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (clinicaltrials.gov) - Dec 18, 2017
P3b, N=347, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Phase classification: P3 --> P3b
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Simultaneous Assessment of FFR and SPECT (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=50, Recruiting, Sponsor: University of Pittsburgh
Phase classification: P3 --> P3b Trial primary completion date: Jul 2018 --> Jul 2020
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Estimating extraction fraction and blood flow by combining first-pass myocardial perfusion and T1 mapping results. (Pubmed Central) - Dec 1, 2017
This was followed 20±5 minutes later by an injection of regadenoson to induce hyperemia...This hybrid approach is especially important when the 5-parameter model alone fails to converge on a unique solution. This work is a good example of exploiting information overlaps between various cardiac MR imaging techniques.
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment closed, Trial primary completion date: Microvascular Blood Flow in Sickle Cell Anemia (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Blood Center of Wisconsin
This work is a good example of exploiting information overlaps between various cardiac MR imaging techniques. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial initiation date: Allograft Dysfunction in Heart Transplant (clinicaltrials.gov) - Oct 31, 2017
P4, N=36, Not yet recruiting, Sponsor: Paul Kim
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Apr 2017 --> Dec 2017
- | Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
Journal: Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis. (Pubmed Central) - Oct 28, 2017
Sarcoid-mediated myocardial inflammation is associated with a regional impairment of coronary circulatory function. The association between immune-suppressive treatment-related alterations in myocardial inflammation and changes in coronary vasodilator capacity suggests direct adverse effect of inflammation on coronary circulatory function in cardiac sarcoidosis.
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial initiation date: Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation (clinicaltrials.gov) - Oct 26, 2017
P1, N=21, Not yet recruiting, Sponsor: Christine Lau, MD
The association between immune-suppressive treatment-related alterations in myocardial inflammation and changes in coronary vasodilator capacity suggests direct adverse effect of inflammation on coronary circulatory function in cardiac sarcoidosis. Initiation date: Aug 2017 --> Dec 2017
- |||| OPL-0401 / Valo Health
Enrollment open: A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI (clinicaltrials.gov) - Oct 4, 2017
P2, N=78, Recruiting, Sponsor: Sanofi
Initiation date: Aug 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease (clinicaltrials.gov) - Oct 3, 2017
P4, N=50, Recruiting, Sponsor: Dipan Shah
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve (clinicaltrials.gov) - Sep 26, 2017
P4, N=75, Recruiting, Sponsor: Duke University
Trial primary completion date: Jun 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial termination: RHINO: Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension (clinicaltrials.gov) - Sep 14, 2017
P=N/A, N=10, Terminated, Sponsor: National Jewish Health
Not yet recruiting --> Recruiting Not yet recruiting --> Terminated; PI left National Jewish Health
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment change: Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction (clinicaltrials.gov) - Aug 22, 2017
P4, N=14, Completed, Sponsor: Paul Kim
Not yet recruiting --> Terminated; PI left National Jewish Health N=18 --> 14
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P4 trial: Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve (clinicaltrials.gov) - Aug 14, 2017
P4, N=75, Not yet recruiting, Sponsor: Duke University
- ||||| OPL-0401 / Valo Health
New P2 trial: A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI (clinicaltrials.gov) - Jul 31, 2017
P2, N=78, Not yet recruiting, Sponsor: Sanofi
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment closed, Trial primary completion date: Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies (clinicaltrials.gov) - Jul 26, 2017
P=N/A, N=44, Active, not recruiting, Sponsor: Daniel S. Berman
N=18 --> 14 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Dec 2018
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET (clinicaltrials.gov) - Jul 13, 2017
P4, N=41, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Dec 2018 Active, not recruiting --> Completed
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia (clinicaltrials.gov) - Jun 23, 2017
P1, N=46, Completed, Sponsor: St. Louis University
Active, not recruiting --> Completed Recruiting --> Completed
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Enrollment change: Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction (clinicaltrials.gov) - Jun 2, 2017
P4, N=18, Completed, Sponsor: Paul Kim
Recruiting --> Completed Not yet recruiting --> Completed | N=40 --> 18
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New trial: Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT (clinicaltrials.gov) - May 31, 2017
P=N/A, N=30, Recruiting, Sponsor: Stanford University
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment closed: Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET (clinicaltrials.gov) - May 17, 2017
P4, N=41, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Not yet recruiting --> Completed | N=40 --> 18 Recruiting --> Active, not recruiting
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics (clinicaltrials.gov) - May 15, 2017
P=N/A, N=68, Active, not recruiting, Sponsor: University of Cincinnati
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Jun 2019
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, Trial primary completion date: REDUCE: Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT (clinicaltrials.gov) - May 12, 2017
P=N/A, N=800, Recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jun 2017 --> Jun 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2017 --> Jan 2018
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Phase classification, Enrollment change: Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging (clinicaltrials.gov) - May 9, 2017
P=N/A, N=49, Completed, Sponsor: University of Cincinnati
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2017 --> Jan 2018 Recruiting --> Completed | Phase classification: P2 --> PN/A | N=75 --> 49
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers (clinicaltrials.gov) - Apr 18, 2017
P1, N=145, Recruiting, Sponsor: University of Michigan
Recruiting --> Completed | Phase classification: P2 --> PN/A | N=75 --> 49 Trial primary completion date: Sep 2018 --> Jun 2018
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System (clinicaltrials.gov) - Apr 5, 2017
P2, N=30, Recruiting, Sponsor: Medical University of South Carolina
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P4 trial: Allograft Dysfunction in Heart Transplant (clinicaltrials.gov) - Apr 5, 2017
P4, N=36, Not yet recruiting, Sponsor: Paul Kim
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, MRI: Whole-Heart Myocardial Blood Flow Quantification Using MRI (clinicaltrials.gov) - Mar 28, 2017
P=N/A, N=160, Recruiting, Sponsor: Cedars-Sinai Medical Center
Trial primary completion date: Sep 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo (clinicaltrials.gov) - Mar 24, 2017
P2, N=20, Recruiting, Sponsor: University of Aarhus
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New trial: REDUCE: Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=800, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) - Mar 20, 2017
P=N/A, N=150, Enrolling by invitation, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Dec 2018
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P1 trial: Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation (clinicaltrials.gov) - Mar 7, 2017
P1, N=21, Not yet recruiting, Sponsor: Christine Lau, MD
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging. (Pubmed Central) - Feb 27, 2017
There was good correlation in the HRR to regadenoson on serial measurements without systematic or proportional biases. Patients with consistently normal HRR had the best prognosis.
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New trial, MRI: Whole-Heart Myocardial Blood Flow Quantification Using MRI (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=160, Not yet recruiting, Sponsor: Cedars-Sinai Medical Center
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment change, Trial primary completion date: Reducing Radioisotope Dose: the Half-Dose CZT Study (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=50, Recruiting, Sponsor: S.M.Chang, MD
Patients with consistently normal HRR had the best prognosis. N=200 --> 50 | Trial primary completion date: Dec 2016 --> Nov 2017
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: RECAD-AF: Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients (clinicaltrials.gov) - Nov 2, 2016
P2, N=32, Completed, Sponsor: University of Utah
N=200 --> 50 | Trial primary completion date: Dec 2016 --> Nov 2017 Recruiting --> Completed
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, Trial initiation date: Simultaneous Assessment of FFR and SPECT (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=50, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease (clinicaltrials.gov) - Oct 11, 2016
P4, N=50, Recruiting, Sponsor: Dipan Shah
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - Aug 10, 2016
P2, N=100, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Jun 2016 --> Oct 2016
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Enrollment change, Trial primary completion date: Characterization of Myocardial Blood Flow Measurements Using Lexiscan (clinicaltrials.gov) - Jul 28, 2016
P4, N=80, Completed, Sponsor: Timothy M. Bateman, MD
Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Completed | N=60 --> 80 | Trial primary completion date: Jan 2016 --> Apr 2016
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date, MRI: Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging (clinicaltrials.gov) - Jul 19, 2016
P4, N=40, Recruiting, Sponsor: Timothy M. Bateman
Recruiting --> Completed | N=60 --> 80 | Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Oct 2016 --> Sep 2017
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Reducing Radioisotope Dose: the Half-Dose CZT Study (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=200, Recruiting, Sponsor: The Methodist Hospital System
Trial primary completion date: Oct 2016 --> Sep 2017 Trial primary completion date: May 2016 --> Dec 2016
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET (clinicaltrials.gov) - Jun 20, 2016
P4, N=50, Recruiting, Sponsor: Brigham and Women's Hospital
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Jun 2017
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Stress CT Perfusion in Patients With Chest Pain (clinicaltrials.gov) - May 13, 2016
P=N/A, N=300, Recruiting, Sponsor: University of Chicago
Trial primary completion date: May 2016 --> Jun 2017 Trial primary completion date: Jun 2017 --> Jun 2018
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment closed, Trial primary completion date: Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics (clinicaltrials.gov) - May 3, 2016
P=N/A, N=68, Active, not recruiting, Sponsor: University of Cincinnati
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2017
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, Trial primary completion date: Reducing Radioisotope Dose: the Half-Dose CZT Study (clinicaltrials.gov) - Mar 23, 2016
P=N/A, N=200, Recruiting, Sponsor: The Methodist Hospital System
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> May 2016
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: RECAD-AF: Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients (clinicaltrials.gov) - Mar 22, 2016
P2, N=32, Recruiting, Sponsor: University of Utah
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> May 2016 Trial primary completion date: May 2014 --> Oct 2016
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease (clinicaltrials.gov) - Mar 16, 2016
P4, N=50, Recruiting, Sponsor: The Methodist Hospital System
Trial primary completion date: May 2014 --> Oct 2016 Trial primary completion date: Aug 2012 --> Jun 2016